The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Sarah P. Blagden, Michaela Serpi et al.|Clinical Cancer Research|2021Cited by 44
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cellsMara Artibani, Ahmed A. Ahmed, Garry Mallett et al.|JCI Insight|2021Cited by 42
The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian CancersZhiyuan Hu, Ahmed Ahmed, Ashwag Albukhari et al.|Clinical Cancer Research|2021Cited by 23
LARP1 regulates metabolism and mTORC1 activity in cancerJames Chettle, Sarah P. Blagden, Colin R. Goding et al.|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1
Table S2 from The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms <i>In Vitro</i> and in a First-In-Human Phase I Clinical TrialHagen Schwenzer, Sarah P. Blagden, Michaela Serpi et al.|Unknown|2024Cited by 0